Imaging and clinical correlates with regorafenib in metastatic colorectal cancer

Khurum Khan,Stefano Cascinu,David Cunningham,Sun-Young Kim,Eiji Oki,Tara Seery,Lin Shen,Salvatore Siena,Christophe Tournigand,Nazim Serdar Turhal,Alain Hendlisz

Cancer Treatment Reviews（2020）

引用 7|浏览0

暂无评分

摘要

•Regorafenib is a tyrosine kinase inhibitor used to treat metastatic CRC.•Timely detection of non-responders to regorafenib may limit unnecessary exposure.•Regorafenib-induced changes in tumor density or vasculature correlate with outcomes.•Imaging data show radiologic markers of response after 2–4 weeks of regorafenib.•Differences between CT, MRI, and PET to identify regorafenib response are discussed.

查看译文

关键词

Regorafenib,Computed tomography,Metastatic colorectal cancer,Magnetic resonance imaging,Positron emission tomography

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要